anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Many drugs, including most antidepressants (SSRIs, many tricyclics), beta-blockers, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme. Although bupropion is not metabolized by this isoenzyme, bupropion and hydroxybupropion are inhibitors of the CYP2D6 isoenzyme in vitro. In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively. The effect was present for at least 7 days after the last dose of bupropion. Concomitant use of bupropion with other drugs metabolized by CYP2D6 has not been formally studied.

Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication. If bupropion is added to the treatment regimen of a patient already receiving a drug metabolized by CYP2D6, the need to decrease the dose of the original medication should be considered, particularly for those concomitant medications with a narrow therapeutic index.
BACKGROUND: Although the pandemic has ended officially, COVID-19 remains impactful. Booster COVID-19 vaccination is still needed to protect individuals against COVID-19 and the disease's harmful consequences. This study investigated the prevalence of the intention to get booster COVID-19 vaccination after receiving the COVID-19 diagnosis and its associated factors among people reporting prior COVID-19.
METHODS: A population-based anonymous telephone survey was conducted in Hong Kong, China from June to August 2022 among Chinese people reporting prior COVID-1 between February and August 2022 and having taken up ≥2 doses of COVID-19 vaccines prior to COVID-19 diagnosis.
RESULTS: The prevalence of the intention to get booster vaccination was 59.2 %. Older age (>60 years), being currently married, not employed full-time, and having chronic diseases were positively associated with the intention to get booster vaccination. Adjusted for the background factors, higher levels of the cognitive factors of perceived susceptibility to COVID-19, perceived acquired moderate-to-strong immunity against COVID-19, and perceived adequate knowledge of COVID-19 were positively associated with the intention to get booster vaccination; stronger perceived severity of prior infection despite vaccination was negatively associated with the intention outcome. In contrast, stronger mental distress due to COVID-19, illness concern, and emotional representation were positively associated with the intention. Self-perceived long COVID status was not a significant factor.
DISCUSSION: The prevalence of the intention to get booster COVID-19 vaccination was limited, especially among younger people reporting prior COVID-19. Health promotion is still required among people reporting prior COVID-19 and may emphasize the significant cognitive factors positively associated with the intention. Future studies are needed to confirm the findings, clarify the role of emotional factors on booster vaccination, and explore other factors of the intention to get booster vaccination among people reporting prior COVID-19.
In a clinical study of COAGADEX in subjects with severe or moderate Factor X deficiency (basal FX:C < 5 IU/dL), the pharmacokinetics of COAGADEX were assessed after intravenous infusion (mean [range] infusion rate 5.9 [1.3-17.1] mL/min) of 25 IU/kg COAGADEX. Pharmacokinetic (PK) parameters were calculated from plasma Factor X:C activity measurements after subtraction of the pre-dose value. The PK assessment was repeated at least 6 months after the first dose. The PK parameters following a single dose are summarized in Table 3. The pharmacokinetics of COAGADEX were similar following the single and repeat dosing.

Incremental recovery in children <12 years of age was assessed at baseline and 6 months after the first dose. Values are summarized in Table 4.

Studies were not conducted to evaluate the impact of gender or renal/hepatic function on the pharmacokinetics of COAGADEX.
Use CGM, with availability of Ambulatory Glucose Profile (AGP) data, to monitor and manage glucose over 12 months, in individuals with type 2 diabetes on insulin with or without other glycemic therapies. Glucose management over the 12 months study period will be in primary care, using "usual care" resources.
The Memory and Aging Program intervention consists of five 2-hour sessions conducted over five consecutive weeks. The content of the program includes: (a) the provision of factual information (i.e., about memory, age-related memory changes, lifestyle factors affecting memory, and memory strategies) in an informal lecture format; and (b) memory intervention (i.e., practice and application of several evidence-based memory strategies) in a hands-on interactive format.
Breast cancer is the most common malignant tumor among women. Approximately 19% to 30% of patients with breast cancer achieve a pathological complete response (pCR) following neoadjuvant therapy, while about 5% to 20% of patients experience disease progression. Increasing evidence suggests the significant role of psychological factors in influencing cancer treatment outcomes. Cancer patients often experience emotional distress, including fear of relapse, anxiety, depression, and low self-esteem, which may persist for many years. Statistics indicate that the incidence of anxiety and depression among cancer patients is 49.69% and 54.90%, respectively, significantly higher than that of healthy individuals (anxiety: 18.37%, depression: 17.50%) in China. There are indications that emotional issues may be linked to cancer treatment, although the underlying mechanisms remain unclear.

This study aims to investigate the relationship between anxiety and depression and the effectiveness of standard neoadjuvant therapy in patients with breast cancer.
FIELD: veterinary science. SUBSTANCE: the present innovation deals with immunological diagnostics of larval cestodoses, echinococcoses, in particular. The suggested method deals with simultaneous preparing primary cell culture out of protoscoleces of cestodes and cultivating protoscoleces' cells. Then one should obtain passaged cell culture and select diagnostically active series of cellular metabolites by applying immunoenzymatic reaction. Also, the method deals with possibility for cryoconservation of passaged culture cells followed the stage of its obtaining. The method in question enables to obtain antigen at 87.09- 95.30% sensitivity and 81.9-90.2% specificity. It could be applied in medicine for obtaining highly sensitive and highly specific antigen for predicting echonococcoses. EFFECT: higher efficiency. 4 ex, 2 tbl
Paclitaxel dosed by actual body surface area and not maxed at BSA 2.0. The Carboplatin dose will be calculated according to the Calvert formula using as estimated glomerular filtration rate from the Cockcroft-Gault formula and will be subject to maximum allowed doses.
The invention discloses an esterase response polymer and application thereof. The esterase response polymer takes a chitosan hydrophilic main chain as a framework, and benzyl modified ursodeoxycholic acid is connected to an amino group of the hydrophilic main chain to be taken as a hydrophobic group, so that the amphiphilic polymer of chitosan grafted ursodeoxycholic acid benzyl derivative groups is formed. The polymer can be used for preparing esterase response blank polymer nano-carriers or esterase response polymer nano-drug carriers. The polymer forms a polymer nano-carrier through self-assembly. The polymer nano-carrier can be loaded with various types of micromolecule and macromolecule drugs to become an esterase response polymer nano-drug carrier, and is particularly suitable for loading water-soluble polypeptide, protein, receptor agonist and nucleic acid drugs for vaccines or gene therapy. The esterase response polymer nano-drug carrier can be administrated by various ways such as intravenous injection, subcutaneous local injection and the like, and has wide clinical applicability.
Trial MV40618 was a randomized double-blind, multicenter, placebo-controlled study to evaluate the efficacy of a single, oral dose of XOFLUZA compared with placebo, for treatment to reduce transmission of influenza virus from otherwise healthy (OwH) IPs aged ≥ 5 to ≤ 64 years to HHCs.

The transmission efficacy analysis was based on 1092 IPs who were randomized within 48 hours of symptom onset to receive either XOFLUZA (N=548) or placebo (N=544), and their influenza-negative household contacts (N=2216 full study HHCs) who were enrolled within 24 hours of IP randomization. IPs of 12 years of age and older received 40 mg or 80 mg of XOFLUZA according to body weight (< 80 kg or ≥ 80 kg, respectively) and IPs from 5 to < 12 years of age received 2 mg/kg XOFLUZA for body weight < 20 kg, or 40 mg for body weight ≥ 20 kg.

The predominant influenza virus type in IPs in this study was influenza A (82.5%), of which the most frequently reported subtype was H1N1(49.3%). The primary efficacy endpoint was transmission of influenza virus by Day 5 (confirmed by RT-PCR with a virus subtype consistent with that of the IP) and the key secondary efficacy endpoint was transmission of influenza virus by Day 5 resulting in symptoms (confirmed by RT-PCR with a virus subtype consistent with that of the IP by Day 5; and at any time displayed symptoms defined as temperature ≥ 38°C plus one respiratory symptom, or one respiratory symptom plus one general systemic symptom, with or without fever in HHCs > 12 years, or temperature ≥ 38°C plus signs or symptoms of an upper respiratory tract infection in HHCs aged < 12 years).

A statistically significant and clinically meaningful reduction in the primary endpoint and a non-statistically significant but clinically meaningful reduction in the key secondary endpoint was seen for XOFLUZA when compared with placebo (see Table 12).
Vaccination for cancers arising from human papillomavirus (HPV) infection holds immense potential, yet clinical success has been elusive. Herein, we describe vaccination studies involving spherical nucleic acids (SNAs) incorporating a CpG adjuvant and a peptide antigen (E711-19) from the HPV-E7 oncoprotein. Administering the vaccine to humanized mice induced immunity-dependent on the oligonucleotide anchor chemistry (cholesterol vs (C12)9). SNAs containing a (C12)9-anchor enhanced IFN-γ production >200-fold, doubled memory CD8+ T-cell formation, and delivered more than twice the amount of oligonucleotide to lymph nodes in vivo compared to a simple admixture. Importantly, the analogous construct with a weaker cholesterol anchor performed similar to admix. Moreover, (C12)9-SNAs activated 50% more dendritic cells and generated T-cells cytotoxic toward an HPV+ cancer cell line, UM-SCC-104, with near 2-fold greater efficiency. These observations highlight the pivotal role of structural design, and specifically oligonucleotide anchoring strength (which correlates with overall construct stability), in developing efficacious therapeutic vaccines.
Patients receive gp100:209-217(210M) emulsified in Montanide ISA-51 SC on day 1 and interleukin-2 SC on days 1-5 and 8-13. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Patients with a CR receive 3 additional courses after achieving CR.
3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") is widely used by young people for its euphoric effects. MDMA releases serotonin (5-HT), norepinephrine (NE), and dopamine through an interaction with the corresponding presynaptic monoamine uptake transporter. 5-HT transport inhibitors block MDMA-induced 5-HT release in vitro or in animals and also attenuate the subjective and cardiovascular response to MDMA in humans. NE transport inhibitors similarly prevent the MDMA-induced release of NE in cell assays and attenuate behavioral effects of MDMA in animals. Effects of the NE transporter inhibitor reboxetine on the response to MDMA in humans are currently investigated. Here we suggest evaluating effects of pretreatment with the combined 5-HT and NE transport blocker duloxetine on the pharmacodynamics and pharmacokinetics of MDMA. The study will use a randomized double-blind cross-over design with four experimental sessions. Duloxetine (120 mg) or placebo will be administered 16 h and 4 h before the administration of MDMA (125 mg) or placebo to 16 healthy volunteers. Subjective and cardiovascular responses and plasma samples for pharmacokinetics will be repeatedly assessed throughout the experiments.
The rate of early neurological deterioration (END) differs in different subtypes of ischaemic stroke. Previous studies showed PLCL2 gene is a novel susceptibility locus for the occurrence of atherosclerosis and thrombotic events. The objective of this research is to examine the efficacy that PLCL2 may have on the risk of END in large artery atherosclerotic (LAA) stroke. Tagged single nucleotide polymorphisms (SNPs) were identified by a strategy of fine-mapping. The genotyping of the selected SNPs was performed by SNPscan. The impact of PLCL2 on indicating the susceptibility of END in LAA patients was evaluated by binary logistic regression. The SNP-SNP interactions of PLCL2 for END was assessed by generalized multifactor dimensionality reduction (GMDR). A total of 1527 LAA stroke patients were recruited, 582 patients (38 %) experienced END. Compared to participants without END, participants experienced END were much older (P = 0.018), more likely to suffer pre-existing diabetes mellitus (P = 0.036), higher frequent in active tobacco users (P = 0.022) and had much higher median NIHSS on admission (P < 0.001). Rs4685423 was identified to be a predictor to the risk of END: the frequency of END in AA genotype patients is lower than that in AC or CC genotype patients (multivariate-adjusted, OR 0.63; 95 % CI 0.49-0.80; P < 0.001). The SNP-SNP interactions analysis indicates rs4685423 has the greatest impacton the risk of END for LAA patients. The time from admission diagnosis to END onset in AA genotype patients is much later than that in CA or CC genotype patients (log-rank, P = 0.005). In summary, the PLCL2 rs4685423 SNP is probably associated with the END risk in LAA stroke patients.
The invention relates to a traditional Chinese medicine compound, in particular to a bone-knitting qili compound and a preparation method thereof. The bone-knitting qili compound provided by the invention comprises native copper, ground beetle, rhizome drynariae, resina draconis, frankincense, myrrh, angelica, rhubarb and borax. The invention compares the main efficacy of the bone-knitting qili compound without single medicinal material and the full prescription compound, i.e. catagmatic effectiveness, finds that six medicinal materials of frankincense, myrrh, rhizome drynariae, resina draconis and the like play an important role in compound efficacy. The invention also creatively selects the main controllable efficacy ingredients in the six medicinal materials, and the ingredients are taken as the basis for identifying quality. By using the medicinal materials with different standard limits to prepare the bone-knitting qili compound to carry out efficacy comparison, the result shows that the bone-knitting qili compound prepared from any one single or multiple medicinal material(s) which satisfies (satisfy) a certain standard limit has obvious better efficacy than the compound which does not meet the requirement.
The room will be kept at 18-20 degrees Celsius. This is within the human thermoneutral zone. It will serve as the control condition.
Sore throat represents one of the main causes of antibiotic overprescription in children. Its management is still a matter of debate, with countries considering streptococcal pharyngotonsillitis a benign and self-limiting condition and others advocating for its antibiotic treatment to prevent suppurative complications and acute rheumatic fever. Italian paediatricians frequently prescribe antibiotics on a clinical basis regardless of microbiological results. Moreover, broad-spectrum antibiotics are inappropriately prescribed for this condition. In this regard, an intersociety consensus conference was issued to promote the judicious use of antibiotic therapy in paediatric outpatient settings. A systematic review of the literature was performed, and updated recommendations were developed according to the GRADE methodology. Antibiotic treatment with amoxicillin (50 mg/kg/day) for 10 days is recommended in all children with proven streptococcal pharyngitis. Benzathine-penicillin could be prescribed in children with impaired intestinal absorption or inability to tolerate enteral intake and in those at high risk of suppurative complications with low compliance to oral therapy. In children with suspected amoxicillin allergy, third-generation cefalosporins for five days are recommended in low-risk patients, and macrolides are recommended in high-risk ones. Candidates for tonsillectomy due to recurrent pharyngitis could be treated with amoxicillin-clavulanic acid, clindamycin, or combined therapy with amoxicillin plus rifampicin for four days, in an attempt to avoid surgery.
PURPOSE: To obtain plasma pharmaceuticals holding coagulation factors which do not contain blood type antibodies by bringing a compsn. which contains undesirable antibodies, etc., and is derived from the blood into contact with a specific resin-antigen conjugate, thereby efficiently removing the undesirable antibodies. CONSTITUTION: The compsn. which contains the undesirable antibodies, such as blood type antibodies, contains >=1 kinds of the coagulation factors and is derived from the blood is brought into contact with the resin-antigen conjugate, such as alkyl methacrylate polymer or microgranular porous glass, which is capable of removing the antibodies without substantially removing the coagulation factor from the compsn. The compsn. is treated in such a manner that the treated compsn. holds >=85%, in average, coagulation factor but does not substantially contain the undesirable antibodies described above. The undesirable antibodies are thus removed from the compsn. which contains the undesirable antibodies, contains >=1 kinds of the coagulation factors and is derived from the blood.
The participant will receive first phantom capsule after complete survey before the test, which include standard clinical intra-vesical pressure measurement in the perioperative period of laparoscopic surgery. The phantom capsule is an equal-weighted device of the same outer shell but without the electric circuits. After the phantom capsule has been passed out, the participant will receive the standard PDT capsule to record measured information continuously. The date of the laparoscopic surgery should be within follow-up day 2 to day 6. Standard clinical intra-vesical pressure measurement will only be applied in the perioperative period of laparoscopic surgery. The participant will still be monitored by standard PDT capsule afterwards. After the PDT capsule passed out, the participant will receive complete checkup again for comparison.
The experimental group will have the same lumbar stabilization exercises performed on the whole body vibration device twice a week for 6 weeks. The frequency of the device will be set to 30 Hz. Exercise duration, frequency, number and variety will be kept equal for the experimental and control groups. Demographic information of the patients, viscoelastic properties of the lumbar region, pain, function, quality of life, lower extremity muscle strength, endurance, balance and proprioception will be evaluated. Measurements will be made before treatment and at the end of 6 weeks of treatment.
The present invention relates to a composition for preventing, alleviating, or treating inflammatory diseases containing extracellular vesicles (EV) derived from a Roseburia spp. strain and/or Bifidobacterium spp. strain. The extracellular vesicles of the present invention reduce damage to an intestinal epithelial cell barrier and infiltration of immune cells in IBD patients, maintain the number of goblet cells, suppress a decrease in a cecal weight and an intestine length associated with intestinal inflammation, suppress secretion of inflammatory cytokines through a change in intestinal flora, and restores mucus secretion of the goblet cells and a tight bonding ability of intestinal epithelial cells so that IBD is alleviated. In addition, as a result of confirming an anti-inflammatory effect of EVs derived from congeneric and heterogeneous strains corresponding to a Roseburia spp. strain or Bifidobacterium spp. strain, it is confirmed that all of the EVs exert a strong anti-inflammatory effect. Accordingly, the strain and the EV derived therefrom of the present invention can be provided as a composition for preventing, alleviating, or treating various inflammatory diseases. The present invention provides a pharmaceutical composition for preventing or treating inflammatory diseases including at least one selected from a group containing extracellular vesicles derived from the Roseburia spp. strain and extracellular vesicles derived from the Bifidobacterium spp. strain as an active ingredient.
Children in this group were examined for intestinal parasites and then treated accordingly. They were follow up for 6 months.
High pressure to treat aggregated interferons, particularly recombinant human interferon-β, to reduce the aggregate content of interferon material. Highly pure, soluble monomeric recombinant interferon-β is prepared in representative embodiments. Multiple strategies may be used in combination that make nonglycosylated IFN-β more amenable to high pressure treatment. It has been found that refolding yields of high pressure treatment can be significantly improved by use of a combination of strategies, including, or example a pre-treatment of the IFN-β that involves solubilizing and then precipitating the protein. This pre-treatment is particularly effective with respect to recombinant IFN-β inclusion bodies recovered from host cells such as  E. coli  cells. According to another strategy, refolding under high pressure is much more effective when the refolding reagent incorporating the IFN-β incorporates a zwitterionic surfactant and/or a cholate salt. When a solubilization and precipitation pre-treatment is used, the effectiveness of the high pressure treatment is further enhanced when the refolding reagent incorporating the protein incorporates a disulfide shuffling chemistry such as cysteine/cystine. According to still yet another strategy, high pressure treatment is more effective when using atypically high treatment pressures. When coupled with purification techniques, these strategies singly or in combination provide a low aggregate or substantially aggregate free, biologically active solution. Biologically active solutions comprising nonglycosylated interferon, said interferon comprising less than about 5 weight percent of protein aggregation has been found to exhibit improved PK/PD characteristics.
Tab Artesunate 50 mg daily for 4 days. Vitamin A 5OOOIU daily for 4 days if \< 1 year. 10,000IU daily for 4 days if \> 1 year. All administered orally.
In total, 25 patients are recruited to form the CABG group. During CABG, RAA tissue is removed as detailed for the AAMs-patch group. However, the tissue is collected as a cryostored sample for later analyses rather than processed to AAMs (Method 4). CABG is performed without epicardial transplantation of AAMs, yet the collagen-based patch material is transplanted onto the epicardium of the scarred myocardium according the same principles as in the AAMs-patch intervention arm.